SIGLEC1 and neoplasm: However, possible stimulation of CD169+ macrophages might be an interesting target for immunotherapy as the uptake of tumor cell material that is released after cell death caused by the neoadjuvant therapy by CD169+ macrophages has been shown to further stimulate anti-tumor immunity [31].